SML2021

MIND4-17

≥98% (HPLC)

• 동의어(들): 5-Nitro-2-{[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio}pyridine
• 실험식(Hill 표기법): C₂₀H₁₅N₅O₃S
• CAS Number: 345989-24-4
• Molecular Weight: 405.43
• MDL number: MFCD01899657
• UNSPSC 코드: 12352200
• NACRES: NA.77

속성

• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to brown
• solubility: DMSO: 2 mg/mL, clear (warmed)
• 저장 온도: 2-8°C
• SMILES string: O=[N+]([O-])C(C=C1)=CN=C1SC2=NN=C(COC3=CC=CC=C3)N2C4=CC=CC=C4
• InChI: 1S/C20H15N5O3S/c26-25(27)16-11-12-19(21-13-16)29-20-23-22-18(14-28-17-9-5-2-6-10-17)24(20)15-7-3-1-4-8-15/h1-13H,14H2
• InChI key: OZUBDKIROJPQGE-UHFFFAOYSA-N

설명

생화학적/생리학적 작용

KEAP1 covalent modifier with therapeutic potential for Huntington′s disease by promoting NRF2 activation.

MIND4-17 is a potent NRF2 (nuclear factor erythroid 2-related factor 2) activator that covalently modifies a critical stress-sensor cysteine (C151) in the BTB domain of the E3 ligase substrate adaptor protein Kelch-like ECH-associated protein 1 (KEAP1), the primary negative regulator of NRF2. MIND4-17 induces NRF2 activation responses in neuronal and non-neuronal cultures (effective conc. 0.1-10 μM) of human, mouse, and rat origins. In addition, MIND4-17 effectively reduces endotoxin-induced IL-6 release from WT as well as YAC128 HD mutant mice-derived primary microglia and astrocytes, however, NRF2 induction by MIND4-17 is shown to be compromised in human Huntington′s diseased (HD) relative to non-disesed neural stem cells due to suppressive influence of the expanded CAG repeat mutation on pathway activation.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H315,H319,H335
• 예방조치 성명서: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• 표적 기관: Respiratory system
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable